PHARMACYTE BIOTECH, INC. (PMCB) Operating income 2017–2026
PHARMACYTE BIOTECH, INC. (PMCB) annual operating income history from SEC filings — each fiscal year as reported.
-$6.9MFY2026 · since FY2017: -$4.4M → -$6.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$6.9M | -56.6% |
| FY2025 | -$4.4M | +48.6% |
| FY2024 | -$8.5M | -32.0% |
| FY2023 | -$6.5M | -47.0% |
| FY2022 | -$4.4M | -21.2% |
| FY2021 | -$3.6M | +5.3% |
| FY2020 | -$3.8M | +6.7% |
| FY2019 | -$4.1M | +41.3% |
| FY2018 | -$7.0M | -57.2% |
| FY2017 | -$4.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PMCB financial trends
PMCB RevenuePMCB Net incomePMCB Net marginPMCB Gross profitPMCB Gross marginPMCB Operating marginPMCB Operating cash flowPMCB Free cash flowPMCB Capital expendituresPMCB Return on equityPMCB Stock buybacksPMCB Dividends paidPMCB Total assetsPMCB Total liabilitiesPMCB Shareholders’ equityPMCB overview →